(LSTA) Lisata Therapeutics, Inc. SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(LSTA) Lisata Therapeutics, Inc. Complete Analysis Pack
Go Beyond the Preview—Access the Full Reference Sources
This Lisata Therapeutics, Inc. SWOT Analysis summarizes the company’s core strengths, weaknesses, market opportunities, and external threats—useful for investment, strategy, or research—and this page includes a real preview/sample of the analysis so you can see the format and depth before buying. Purchase the full version to receive the complete ready-to-use SWOT report.
Strengths
3 clinical programs in Phase II/IIb
Lisata Therapeutics has 3 mid-stage clinical programs, HONEDRA, XOWNA, and CLBS201, across Phase II/IIb. They target critical limb ischemia, coronary microvascular dysfunction, and chronic kidney disease, so one pipeline can drive several readouts. That mix gives Lisata more than one shot at value creation as each program reaches data milestones.
HONEDRA with SAKIGAKE designation
HONEDRA’s SAKIGAKE designation in Japan gives Lisata Therapeutics, Inc. a clear regulatory edge, since the program is meant to speed priority development and review for promising therapies. That can lift the asset’s visibility with regulators and partners, while signaling strong innovation potential. In a market where faster review can matter, this status can improve the program’s strategic profile.
Focused on vascular and renal diseases
Lisata Therapeutics, Inc. is focused on vascular and renal diseases, including critical limb ischemia, coronary microvascular dysfunction, and chronic kidney disease. That targets large unmet needs: chronic kidney disease affects about 37 million U.S. adults, and critical limb ischemia carries high amputation and death risk. A tight disease focus can sharpen trial design, payer messaging, and commercial execution.
Founded in 1980
Lisata Therapeutics was founded in 1980, giving it about 46 years of operating history in 2026. That long run can support deeper institutional knowledge, steadier development processes, and better recall of what works across biotech cycles. It also signals durability, since the Company has stayed active through multiple funding, regulatory, and market shifts.
- Founded in 1980
- About 46 years of history
- Supports continuity and know-how
- Shows survival across industry cycles
CD34+ cell therapy and tissue-repair platform
Lisata Therapeutics, Inc.'s CD34+ cell-therapy platform is a real strength because it targets tissue repair and disease reversal, not just symptom control. CLBS201 adds depth beyond a single asset, showing the platform can support more than one program. In regenerative medicine, that kind of differentiated biology can create more durable value than a one-drug story.
- Targets repair, not just symptoms
- CLBS201 broadens platform depth
- Stands out in regenerative medicine
Lisata’s 3-Asset Pipeline and Japan Edge Support a Differentiated Growth Story
Lisata Therapeutics, Inc. has 3 mid-stage assets in Phase II/IIb, giving it multiple near-term readouts and reducing single-asset risk. HONEDRA also has SAKIGAKE status in Japan, a regulatory edge that can speed review. Its CD34+ platform and focus on vascular and renal disease support a differentiated story.
| Strength | Data |
|---|---|
| Pipeline depth | 3 Phase II/IIb programs |
| Regulatory edge | HONEDRA SAKIGAKE |
| Platform | CD34+ cell therapy |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing Lisata Therapeutics, Inc.’s business strategy
Editable Excel File
Provides a quick Lisata Therapeutics, Inc. SWOT snapshot to reduce research friction and speed decision-making.
Reference Sources
Lists primary, reputable sources (trials, SEC filings, peer‑reviewed studies) to speed due diligence and verify Lisata Therapeutics’ market, pricing, and competitive claims.
Weaknesses
No approved commercial products
Lisata Therapeutics remains a clinical-stage biopharmaceutical company, so it still has no approved commercial product or product sales. That leaves 2025-2026 results tied to collaboration and grant income, while R&D spending and trial outcomes drive performance. Until an FDA-approved product reaches market, cash burn and dilution risk stay tied to clinical and regulatory progress.
All lead assets remain in Phase II/IIb
Lisata Therapeutics, Inc. still has no lead asset in late-stage testing: HONEDRA is in Phase II, XOWNA is in Phase IIb, and CLBS201 remains in development. That leaves the pipeline exposed to high trial failure risk and long approval timelines. Without Phase III data, near-term revenue visibility stays weak and financing pressure can rise.
Only 3 named clinical candidates
Lisata Therapeutics, Inc. has only 3 named clinical candidates, so the pipeline is highly concentrated. That means each trial result carries outsized impact on valuation and cash use, while one setback can weaken the whole story. With only 3 programs, near-term diversification is limited, and the company has less room to offset delays or clinical misses.
High dependence on trial milestones
Lisata Therapeutics, Inc. is still a clinical-stage company, so its case rests on trial enrollment, endpoint success, and clean readouts. If a study slips by even one quarter, the whole timeline can move, because valuation is tied to the next data point rather than current sales.
- Trial delays can slow value creation
- Endpoint misses can reset the thesis
- Regulatory timing adds execution risk
That makes milestone execution the main weakness: fewer buffers, higher sensitivity to data timing, and more downside if patient recruitment or regulatory review lags.
Multiple name changes since 1980
Lisata Therapeutics, Inc. has changed names several times since 1980, from NeoStem, Inc. to Caladrius Biosciences, Inc., then to Lisata Therapeutics, Inc. in 2022. That kind of rebranding can weaken market recall and make the Company harder to track across older filings, news, and investor materials. It can also lengthen the time needed for long-term shareholders to connect the current story with the prior identity.
- NeoStem, Inc. to Caladrius Biosciences, Inc.
- Renamed Lisata Therapeutics, Inc. in 2022
- Can dilute brand recognition
- Can disrupt investor memory
Lisata's revenue gap and pipeline risk stay high
Lisata Therapeutics, Inc. remains weak on revenue because it is still clinical stage and has no approved product sales. Its 3 named candidates are concentrated in Phase II to Phase IIb, so one trial miss can hit valuation hard. Cash burn and dilution risk stay high until a late-stage readout or approval improves funding visibility. Rebranding since 2022 can also limit investor recall.
| Weakness | Data point |
|---|---|
| No sales | Clinical-stage only |
| Pipeline depth | 3 named candidates |
| Stage risk | Phase II to IIb |
| Brand history | Renamed in 2022 |
Preview Before You Purchase
Lisata Therapeutics, Inc. Reference Sources
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; buy now to unlock the complete, editable version covering Lisata Therapeutics' strengths, weaknesses, opportunities, and threats in detail.
Opportunities
HONEDRA Japan development pathway
HONEDRA’s SAKIGAKE designation in Japan can speed review and raise its profile with regulators, which matters in a market of about 123 million people. Under Japan’s SAKIGAKE pathway, review can be shortened to roughly 6 months in some cases, improving the odds of an earlier launch. If Lisata Therapeutics, Inc. wins a strong outcome, Japan could become a major regional commercial base for HONEDRA.
XOWNA Phase IIb data in coronary microvascular dysfunction
XOWNA’s Phase IIb readout in coronary microvascular dysfunction could be a key de-risking event for Lisata Therapeutics, Inc. Positive data would push the program closer to late-stage development and raise its odds of becoming a larger cardiovascular asset. It would also widen Lisata Therapeutics, Inc.’s reach beyond its core focus and give investors a clearer shot at a new heart-disease market.
CLBS201 in chronic kidney disease not on dialysis
CLBS201 in chronic kidney disease not on dialysis could address a large unmet need: the CDC says 1 in 7 U.S. adults has CKD, and most are not yet on dialysis. That patient pool is far bigger than the dialysis segment, so even modest clinical success could expand Lisata Therapeutics, Inc.'s renal franchise. If efficacy holds, the program could open a broader commercial path in a high-burden market.
Partnerships with larger biopharma
Lisata Therapeutics, Inc.’s early-stage pipeline still leaves room for a larger biopharma partner to fund late-stage work, add development know-how, and widen access across regions. That can also lower the cash burn and execution risk tied to going solo. For a small biotech, a partner can turn one lead asset into a broader commercial path.
- Funding for later trials
- Better regulatory and launch support
- Lower solo-development burden
Expansion into regenerative medicine indications
Lisata Therapeutics, Inc.'s platform is built to repair damaged tissue and slow disease progression, so it can fit more than one indication. Its lead asset, certepetide (CEND-1), is already being tested across cancer and tissue-injury settings, which supports extension into new regenerative medicine uses. Each added indication can widen the addressable market and spread development risk.
- Platform may fit multiple disease areas.
- More indications can expand market size.
- Same mechanism can support pipeline reuse.
Lisata’s Japan Fast Track Could Unlock a Faster, Broader Growth Story
HONEDRA’s SAKIGAKE path in Japan could shorten review to about 6 months, giving Lisata Therapeutics, Inc. a faster route into a 123 million-person market. XOWNA’s Phase IIb readout in coronary microvascular dysfunction is a key catalyst that could de-risk the pipeline and broaden Lisata Therapeutics, Inc. beyond oncology. CLBS201 also targets a large CKD pool, since 1 in 7 U.S. adults has chronic kidney disease.
| Opportunity | Data point |
|---|---|
| HONEDRA Japan | ~6-month review; 123M market |
| XOWNA | Phase IIb catalyst |
| CLBS201 | 1 in 7 U.S. adults with CKD |
Threats
Phase II and Phase IIb clinical failure risk
Lisata Therapeutics, Inc.'s core value still depends on certepetide in Phase II/IIb, so the risk of missing a primary endpoint is real. Mid-stage oncology trials often enroll only dozens to low hundreds of patients, which makes efficacy noise and safety signals harder to dismiss. One setback at this stage can cut the stock fast because there is no late-stage data buffer.
Regulatory uncertainty across programs
Even with SAKIGAKE designation, Lisata Therapeutics, Inc. still must prove safety, efficacy, and CMC (chemistry, manufacturing, and controls) for each asset. PMDA and FDA reviews can add 6-12 months or more if data gaps appear, lifting trial and filing costs. With only one lead asset, certepetide, any delay can hit the whole pipeline and stretch cash use.
Competition in vascular and renal therapeutics
Lisata Therapeutics, Inc. faces crowded vascular and renal fields where established drugs already generate multi-billion-dollar sales and newer cell-therapy programs are advancing fast. Larger biopharma firms can outspend on trials, manufacturing, and sales, while more than a dozen renal and vascular programs can chase the same patients. That competition can weaken Lisata Therapeutics, Inc.'s partnering leverage and limit share gains.
Capital needs of a clinical-stage biotech
Lisata Therapeutics, Inc. faces a heavy capital load because clinical-stage biotech firms must keep funding trials before any product sales start. Phase 2 and Phase 3 studies can cost millions of dollars, so Lisata may need more equity, debt, or partnership cash to keep programs moving. That raises dilution risk and can strain the balance sheet if financing terms turn weak.
- Ongoing trial spend needs fresh capital
- No approved product means no product cash
- New funding can dilute shareholders
- Weak markets can pressure liquidity
Cell therapy manufacturing and scale-up risk
Cell therapy manufacturing is a real scale-up risk because each dose can be patient-specific, so even small errors in identity, potency, or sterility can stop a batch. For Lisata Therapeutics, Inc., any delay in process transfer, quality control, or cold-chain supply can push trials back and lift commercialization costs. That makes timelines less predictable and raises execution risk.
- Complex, patient-specific production
- Quality and sterility bottlenecks
- Supply-chain delays can slow trials
- Scale-up failures can raise launch risk
Lisata Faces High Clinical Risk as One Asset and Funding Pressure Loom
Lisata Therapeutics, Inc. still carries high clinical risk because certepetide remains in Phase II/IIb, and one missed endpoint could erase most near-term value. With only one lead asset, any delay can hit the whole pipeline and force more funding. Competition and trial scale-up also raise the odds of dilution and timeline slips.
| Threat | Data |
|---|---|
| Lead asset risk | 1 lead asset; Phase II/IIb |
| Review delay | 6-12 months+ |
| Funding pressure | No approved product cash flow |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.